Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110)

Autor: Heinrich, Kathrin, Modest, Dominik P., Ricard, Ingrid, Fischer von Weikersthal, Ludwig, Decker, Thomas, Kaiser, Florian, Graeven, Ullrich, Uhlig, Jens, Schenk, Michael, Freiberg-Richter, Jens, Peuser, Bettina, Denzlinger, Claudio, Giessen-Jung, Clemens, Stahler, Arndt, Michl, Marlies, Held, Swantje, Jung, Andreas, Kirchner, Thomas, Stintzing, Sebastian, Heinemann, Volker
Zdroj: In European Journal of Cancer April 2021 147:128-139
Databáze: ScienceDirect
Externí odkaz: